1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Cytokinetics Rocked By Another Omecamtiv Setback

But Hope Remains For Subpopulation

 
• By Ayisha Sharma

The biotech’s cardiology asset has failed an advanced study focused on exercise capacity in heart failure, having underwhelmed observers with past data, but hope remains that the LVEF subset could be a saving grace.  

The white heart pills on a colored background. The concept of a healthy life. Heart disease. Arrhythmia, heart failure. Health problem.
More Than Two Million People In The US Have Severe Heart Failure • Source: Alamy

Cytokinetics, Inc.’s omecamtiv mecarbil has disappointed in yet another Phase III study of heart failure with reduced ejection fraction (HFrEF), but the firm is holding on to the hope that it could still benefit a specific patient subpopulation.

Omecamtiv missed the 276-patient placebo-controlled METEROIC-HF study’s primary endpoint of change from baseline in peak oxygen (pVO2) uptake at week...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 
• By Alaric DeArment

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

More from R&D

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 
• By Alaric DeArment

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.